Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,001 public trials 2,038 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, not recruiting

A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations

NCT03793140

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +16 more
Locations
  • City of Hope Duarte, California, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
View Trial Details
Active, not recruiting

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06223516

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Mayo Clinic Arizona /ID# 260799 Phoenix, Arizona, United States
  • Mayo Clinic Hospital Jacksonville /ID# 262808 Jacksonville, Florida, United States
  • Sylvester Comprehensive Cancer Center /ID# 260798 Miami, Florida, United States
  • University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 261050 Ann Arbor, Michigan, United States
View all 15 locations
View Trial Details
Active, not recruiting

Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL

NCT02682641

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Hospital Clínic de Barcelona Barcelona, Spain
  • Hospital de la Santa Creu i Sant Pau Barcelona, Spain
  • Hospital Universitario Vall d'Hebron Barcelona, Spain
  • Institut Català d'Oncologia Barcelona, Spain
View all 15 locations
View Trial Details
Active, not recruiting

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

NCT03236428

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations
  • Pacific Cancer Care Monterey, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
View Trial Details
Active, not recruiting

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

NCT06192888

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Dana Farber Cancer Institute (Data Collection and Specimen Analysis) Boston, Massachusetts, United States
  • Mayo Clinic (Data Collection Only) Rochester, Minnesota, United States
  • Washington University (Data Collection Only) St Louis, Missouri, United States
  • Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
View Trial Details
Active, not recruiting

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

NCT04756726

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +20 more
Locations
  • Mayo Clinic Phoenix, Arizona, United States
  • University of California-San Francisco San Francisco, California, United States
  • Colorado Blood Cancer Institute (Sarah Cannon Research Institute) Denver, Colorado, United States
  • Mayo Clinic Jacksonville, Florida, United States
View all 13 locations
View Trial Details
Active, not recruiting

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

NCT02586857

Conditions
Astrocytoma, Chronic Disease, Disease Attributes, +22 more
Locations
  • Research Site Los Angeles, California, United States
  • Research Site Palo Alto, California, United States
  • Research Site Boston, Massachusetts, United States
  • Research Site Boston, Massachusetts, United States
View Trial Details
Active, not recruiting

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

NCT02717611

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations
  • Research Site Tucson, Arizona, United States
  • Research Site Concord, California, United States
  • Research Site La Jolla, California, United States
  • Research Site Palo Alto, California, United States
View all 23 locations
View Trial Details

Related conditions